stockrow
Saturday 7 November 2026
Export PYPD’s income statement to Excel — free account
PolyPid Ltd.
PYPD Healthcare Biotechnology
- EPS
- +55.1%
- Free cash flow
- −65.0%
- Total debt
- −88.4%
Quarter to June 2026, against a year earlier
6.09
0.42
+7.41%
Follow PYPD
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 21 | 10 | 25 | +9.1% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | 0.0 pt | ||||||
| EBT | (11) | (54) | 6 | (7) | (37) | (43) | (39) | (24) | (29) | (34) | (32) | +13.0% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (11) | 0 | 6 | (7) | (37) | (43) | (40) | (24) | (29) | (34) | (50) | +13.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (1.05) | (4.45) | 316.67 | (368.67) | (122.22) | (67.87) | (60.96) | (16.99) | (4.91) | (2.09) | (1.48) | +7.9% | ||||||
| Cash flow | (0.73) | (0.93) | (891.87) | (928.24) | (67.68) | (51.95) | (52.99) | (12.27) | (3.71) | (1.70) | (3.37) | +9.8% | ||||||
| Capex | 0.00 | 0.00 | (164.38) | (47.01) | (2.45) | (4.26) | (2.73) | (0.14) | (0.01) | (0.01) | (0.02) | n/m | ||||||
| Free cash flow | (0.73) | (0.93) | (1,056.26) | (975.24) | (70.13) | (56.21) | (55.72) | (12.41) | (3.73) | (1.72) | (3.40) | +9.9% | ||||||
| Book value | 0.76 | (2.16) | (4,369.52) | 998.98 | 228.07 | 57.68 | 9.00 | (1.49) | 1.30 | 0.67 | 0.24 | (1.3%) | ||||||
| Shares, m | 13 | 13 | 0 | 0 | 0 | 1 | 1 | 1 | 6 | 16 | 20 | +2.3% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (10) | (12) | (17) | (17) | (22) | (32) | (34) | (17) | (22) | (28) | (76) | +12.4% | |||||
| Capex | (1) | (2) | (3) | (1) | (1) | (3) | (2) | 0 | 0 | 0 | (1) | (9.9%) | ||||||
| Free cash flow | (10) | (12) | (20) | (18) | (22) | (35) | (36) | (17) | (22) | (28) | (77) | +12.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 17 | 15 | 4 | 25 | 44 | 27 | 6 | (1) | 4 | 7 | 2 | (8.4%) | |||||
| Net debt | (18) | (18) | (8) | (27) | (45) | (33) | (2) | 5 | (8) | (12) | (7) | (4.1%) | ||||||
| Shareholders’ equity | 10 | (29) | (82) | 19 | 73 | 36 | 6 | (2) | 8 | 11 | 5 | +1.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (66.32) | (614.88) | 35.09 | (28.63) | (78.31) | (70.95) | (112.69) | (115.45) | (142.99) | (143.79) | (119.05) | (77.5) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | (58.83) | (802.55) | (562.36) | (533.88) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 22.84 | 96.48 | (6.95) | 8.16 | 577.80 | (78.36) | (189.32) | (1,278.60) | (1,038.73) | (366.29) | (243.59) | (389.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | 58 | 69 | 79 | 69 | 79 | 61 | 62 | — | +1.1% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 25 Oct 2026
PolyPid Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CHRS Coherus Oncology, Inc. | $115.7M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| PYPD PolyPid Ltd. | $115.2M | — (loss-making) | — | — | n/m | −64.96% (below 0%: shrinking) | 0.00% | 0.00% | |
| FHTX Foghorn Therapeutics Inc. | $113.1M | — (loss-making) | — (loss-making) | +112.68% (above 0%: growing) | n/m | +14.88% (above 0%: growing) | 100.00% | (54.78%) | Compare |
| ENGN enGene Therapeutics Inc | $112.6M | — (loss-making) | — | — | n/m | +28.07% (above 0%: growing) | — | 0.00% | Compare |
| NKTX Nkarta, Inc. | $112.5M | — (loss-making) | — | — | n/m | −29.19% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CDXS Codexis, Inc. | $111.7M | — (loss-making) | — (loss-making) | −2.69% (below 0%: shrinking) | n/m | +48.60% (above 0%: growing) | 76.45% | (75.29%) | Compare |
| ARMP Armata Pharmaceuticals, Inc. | $111.5M | — (loss-making) | — (loss-making) | +15.72% (above 0%: growing) | n/m | −17.98% (below 0%: shrinking) | 100.00% | (410.84%) | Compare |
| HUMA Humacyte, Inc. | $109.9M | — (loss-making) | — (loss-making) | +34.88% (above 0%: growing) | n/m | +17.85% (above 0%: growing) | (203.20%) | (6,649.26%) | Compare |
| NERV Minerva Neurosciences, Inc | $109.8M | — (loss-making) | — (loss-making) | — | n/m | −553.48% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $112.1M | — | — | +34.88% | — | −1.55% | 70.35% | (65.03%) |